Validation of miRNA biomarkers for the early diagnosis of lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017455

Enrollment

200

Registered

2019-07-23

Start date

2019-06-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer C34

Interventions

Group 1: Part I: Patients, with having a potentially pathologic lung finding, will be enrolled for this study. Blood samples will be taken and a miRNA profile for the diagnosis of NSCLC will be create

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female patient with suspected pneumological pathology finding 2. Signed consent 3. Patient is at least 18 years old

Exclusion criteria

Exclusion criteria: Patient is younger than 18 years

Design outcomes

Primary

Measure	Time frame
Demonstration of the sensitivity and specificity of the HBDx miRNA signature for the diagnosis of NSCLC using microarray technology.	—

Secondary

Measure	Time frame
Demonstrate the evidence of therapeutic success in patients with NSCLC also at the miRNA level using HBDx microarray technology	—

Countries

Germany

Contacts

Public ContactChristian Schumann

Klinikverbund Kempten-Oberallgäu, Klinikum Immenstadt

pneumologie.sekretariat-immenstadt@kv-keoa.de0049 8323 910-8171

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026